Aron Feingold

Aron Feingold has more than 15 years of experience in biotech and pharmaceutical strategic communications. She is currently the VP of Investor Relations and Corporate Communications at Geron, a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. In her 2+ years with Geron, Aron has led investor relations and corporate communications activities related to Geron’s FDA approval of RYTELO™ (imetelstat) for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia, associated regulatory filings, preparation for commercialization and through three equity financings. Before that, she served as VP, Investor Relations and Corporate Communications at genomic medicine company Sangamo Therapeutics, where she built the communications department and led corporate positioning and branding, investor messaging, product communications and internal communications. Prior to that, she led product communications at Pfizer for oncology drugs XTANDI® and TALZENNA®. Aron joined Pfizer following its acquisition of Medivation, where she led product communications. Aron started her career at Ruder Finn in New York City, where she held roles of increasing responsibility, including leading the Healthcare Media Practice. Aron graduated magna cum laude with a B.A. in English from Carleton College in Northfield, MN. Aron lives in Berkeley, California – around ten minutes from where she grew up – with her husband, 1-year old daughter and her pocket pitbull. Favorite activities when she’s not working include spending time with family, cooking, hiking, wine tasting and gardening. Fun facts about Aron include: she is writing a recipe book with her husband, she trekked to the base camp of Mt. Everest in 2017, and she is a published haiku poet.